A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension
Status:
Recruiting
Trial end date:
2025-04-25
Target enrollment:
Participant gender:
Summary
This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel
group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs.
placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in
212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory
SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of
which is a diuretic).